In a 100 mg immediate-release oral tablet core with a total core mass of 250 mg, ciprofibrate pharma grade API is loaded at 40.0% w/w. At this drug load, the powder blend falls into a cohesive, high-solids regime when the API is micronized to a volume-median particle size of 10–20 µm or smaller, because high specific surface area reduces bulk density and promotes agglomeration. Direct compression is generally not the preferred route for this high-load micronized weak acid; instead, the API is preblended with lactose monohydrate or microcrystalline cellulose and processed through high-shear wet granulation in a 300–600 L granulator, with binder solution added at 0.5–1.5% w/w of dry mass using hypromellose or povidone. The granulated mass is transferred to a fluid-bed dryer where inlet air temperature is held at 55–65 °C and product temperature is maintained below 45 °C until loss on drying is 1.5–2.5% w/w. After dry sieving through a 1.0 mm oscillating granulator, the granules are lubricated with magnesium stearate at 0.5–1.0% w/w and compressed on a rotary tablet press with 10–20 kN mean compression force and a target hardness of 60–100 N. Finished tablet cores are sampled at press start-up, mid-run, and end-run, with content uniformity measured by HPLC according to Ph. Eur. 2.9.6; acceptance is typically AV ≤ 15 for 10 units. Disintegration is assessed by Ph. Eur. 2.9.1 in water at 37±2 °C, with a limit of ≤ 15 min. Dissolution testing under Ph. Eur. 2.9.3 requires a justified medium that maintains sink conditions for the weak acid; for a poorly soluble acid, the use of a surfactant or pH 6.8 phosphate buffer is evaluated against the reference product rather than fixed in the API monograph. The terminal finished product type is an immediate-release ciprofibrate tablet, 100 mg, intended for once-daily oral administration in adult hyperlipidaemia management. The product is released against the relevant ciprofibrate pharmacopoeial monograph where applicable, with elemental impurities controlled to ICH Q3D(R2) limits, organic impurities controlled under ICH Q3A(R2), and stability established by ICH Q1A(R2) conditions at 25 °C/60% RH and 40 °C/75% RH.

What Limits Content Uniformity When Micronized Ciprofibrate Is Transferred to Two-Piece Capsules?

Content uniformity in two-piece hard capsules is limited primarily by the combination of high API proportion, low particle size, and the floodable or cohesive flow character of micronized ciprofibrate. For a 100 mg strength filled into a size 1 hard gelatin or HPMC capsule with a nominal fill mass of 280–320 mg, the API fraction is 31.3–35.7% w/w; the exact ratio is set by tap density and the selected capsule body volume. The blend is usually roller-compacted rather than directly filled because micronized API with lactose or mannitol segregates in the hopper and produces erratic tamping-pin weight control. Roller compaction at roll pressure of 40–80 bar and gap of 1.5–2.5 mm creates ribbons that are milled through a 1.0 mm screen to produce granules with a target size fraction of 150–710 µm. These granules are then filled on an intermittent-motion or continuous-motion capsule filler fitted with either dosator or tamping-pin dosing; fill weight control is monitored by 100% weight checkweighing or periodic gravimetric verification every 30 min.

In-process content uniformity follows Ph. Eur. 2.9.6 or USP <905>, with at least 3 stratified sampling positions across the hopper, beginning, middle, and end of the filling run. Elemental impurities are mapped against ICH Q3D(R2), and the capsule shell supplier is qualified for bovine spongiform encephalopathy/TSE risk according to Ph. Eur. 5.1.7 or relevant EMA guidance. The terminal finished product type is a hard-shell capsule, 100 mg, for oral administration; dissolution is tested with Ph. Eur. 2.9.3 apparatus I or II and should be correlated with the reference capsule during development. A process bottleneck commonly observed on high-speed capsule fillers is the build-up of micronized API on the dosator pin or tamping pins, which shifts fill accuracy after 2–4 h of continuous operation; this is controlled by cleaning cycles, controlled humidity, and the use of force feeders set at low speed to avoid shear-induced static charge.

Granule-based ciprofibrate dosage forms intended for oral administration in adults who cannot swallow tablets or capsules are prepared as unit-dose sachets, with a typical fill mass of 1.0 g per 100 mg dose, equivalent to an API fraction of 10.0% w/w. The proportion is lower than in tablet or capsule cores because the dose is dispersed in a larger mass of soluble or swellable carrier excipients to improve wetting and reduce the risk of localized high concentration in the oral cavity or enteral feeding tube. The manufacturing route is fluid-bed top-spray granulation, in which ciprofibrate is suspended or dissolved in the binder dispersion and sprayed onto a fluidized bed of mannitol, sorbitol, or maltodextrin. Inlet air temperature is normally set between 50 °C and 65 °C to maintain product temperature below 40 °C and limit thermal stress on the API. Granules are dried to a loss-on-drying specification of ≤ 2.0% w/w and passed through a sieving stack to confirm a target granule size range of 150–710 µm, using Ph. Eur. 2.9.38 particle-size distribution by analytical sieving. Each sachet is filled by volumetric or gravimetric auger dosing under controlled humidity, and the sealed sachet is checked for fill weight and seal integrity. Content uniformity of the filled sachets is tested by Ph. Eur. 2.9.6, while microbial quality is monitored according to Ph. Eur. 5.1.4 because oral granules are not sterile. The packaging material, typically polyester/aluminium/polyethylene laminate or PVDC-coated aluminium, is qualified for water vapour transmission under ISO 15106-3 or equivalent, and the finished sachet is placed on stability according to ICH Q1A(R2). The terminal finished product type is a single-dose oral granule sachet, 100 mg, dispersed in water or a specified soft food immediately before administration; this format is used in dysphagia management and in jurisdictions where granules are permitted as an alternative to solid oral dosage forms.

When Ciprofibrate Acid Must Be Processed into a Lipid-Based Injectable under Annex 1 Conditions

The formulation problem for injectable ciprofibrate is dominated by the low aqueous solubility of the free acid and the absence of a harmonized pharmacopoeial monograph for a parenteral ciprofibrate product. Published data for this specific configuration is limited, and the route is not a standard marketed parenteral dosage form in major pharmacopoeias. Development work therefore proceeds through a lipid emulsion or mixed-micelle system, in which the API is first dissolved in a biocompatible oil phase such as medium-chain triglycerides or soybean oil. Early-stage solubility screening brackets the API input at 0.1–0.5% w/v; for a 5 mg/mL target concentration, the API-to-oil ratio, phospholipid emulsifier content, and aqueous phase pH must be justified because ciprofibrate as a weak acid may partition out of the oil phase during steam sterilization. The emulsion premix is prepared with a high-shear rotor-stator mixer at 8,000–15,000 rpm for 15–30 min, followed by high-pressure homogenization at 800–1,200 bar for 5–8 discrete passes through a Microfluidizer-type processor. Droplet size is monitored by laser diffraction or photon correlation spectroscopy, with a mean droplet diameter of <500 nm and a large-droplet tail measured by USP <729> as the population-weighted percentage of fat globules greater than 5 µm not exceeding 0.05%.

Because the emulsion cannot be reliably sterilized by 0.22 µm filtration without removing the oil droplets, terminal steam sterilization at 121 °C for 15 min is used; this imposes a forced-degradation study burden under ICH Q1A(R2) and ICH Q1B photostability. The finished injectable product is a lipid-based or micellar sterile emulsion for intravenous administration under an investigational protocol or hospital-pharmacy preparation; it is not currently a standard marketed ciprofibrate injection. Compliance is controlled by EU GMP Annex 1 for sterile manufacturing, Ph. Eur. 5.1.1 for sterility, Ph. Eur. 2.6.1 for sterility test method, USP <729> for lipid injectable emulsion globule size, and ICH Q3D(R2) for elemental impurities in the parenteral route. The operational boundary is narrow because the same input energy that reduces droplet size can also induce drug precipitation or phospholipid hydrolysis; therefore, homogenization pass count and thermal exposure after API incorporation are controlled as critical process parameters rather than fixed recipe values.

Dry Granulation Footprint in Ciprofibrate Tablets for Moisture-Limited Manufacturing Lines

Manufacturing sites that cannot run aqueous granulation due to plant constraints use roller-compacted ciprofibrate granules for immediate-release tablets or capsule intermediates. The API proportion remains 33.3–40.0% w/w when a 100 mg dose is compacted into a 250–300 mg core. Ciprofibrate is preblended with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide, then compacted into ribbons at roll pressure 30–70 bar and ribbon thickness 1.5–2.0 mm. Ribbons are milled with an oscillating sieve mill at 800–1,200 rpm; the resulting granule fraction is controlled at 150–500 µm to minimize segregation and ensure die filling. The dry-granulation route eliminates the heat and moisture burden of fluid-bed drying, but can re-expose unencapsulated micronized API on granule surfaces after milling, which increases dust generation and requires containment. Tablets are compressed on a high-speed rotary press with 20–40 kN compression force depending on core thickness; hardness is adjusted to 80–120 N to survive film coating. Content uniformity is verified by Ph. Eur. 2.9.6, and dissolution is assessed by Ph. Eur. 2.9.3 with a validated medium. The compliance framework includes ICH Q3D(R2), ICH Q3A(R2), and ICH Q1A(R2), while process validation follows EU GMP Part II. The terminal finished product type is an immediate-release ciprofibrate tablet, 100 mg, produced on a dry-granulation line.